Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
60
ANAB Quote, Financials, Valuation and Earnings
Last price:
$60.51
Seasonality move
:
-7.42%
Day range:
$54.18 - $62.69
52-week range:
$15.12 - $62.69
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
7.73x
P/B ratio:
45.06x
Volume:
1.1M
Avg. volume:
429.4K
1-year change:
297.05%
Market cap:
$1.7B
Revenue:
$234.6M
EPS (TTM):
-$0.52
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ANAB
AnaptysBio, Inc.
|
$87.1M | $0.93 | -10.1% | -33.05% | $70.08 |
|
ABBV
AbbVie, Inc.
|
$16.4B | $2.65 | 10.27% | 318.58% | $248.69 |
|
ESPR
Esperion Therapeutics, Inc.
|
$166.1M | $0.34 | 65.71% | -98.39% | $6.87 |
|
NKTR
Nektar Therapeutics
|
$10.4M | -$3.50 | -5.98% | -735.41% | $129.86 |
|
RIGL
Rigel Pharmaceuticals, Inc.
|
$68.7M | $1.20 | 19.45% | 39.53% | $51.20 |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$59.3M | -- | 8.46% | -- | $14.88 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ANAB
AnaptysBio, Inc.
|
$60.55 | $70.08 | $1.7B | -- | $0.00 | 0% | 7.73x |
|
ABBV
AbbVie, Inc.
|
$236.19 | $248.69 | $417.6B | 100.02x | $1.73 | 2.82% | 6.84x |
|
ESPR
Esperion Therapeutics, Inc.
|
$2.91 | $6.87 | $695.7M | -- | $0.00 | 0% | 1.89x |
|
NKTR
Nektar Therapeutics
|
$71.11 | $129.86 | $1.2B | -- | $0.00 | 0% | 73.32x |
|
RIGL
Rigel Pharmaceuticals, Inc.
|
$29.63 | $51.20 | $537.8M | 1.57x | $0.00 | 0% | 1.89x |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$8.20 | $14.88 | $484.7M | -- | $0.00 | 0% | 2.24x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ANAB
AnaptysBio, Inc.
|
88.65% | -0.489 | 21.65% | 8.94x |
|
ABBV
AbbVie, Inc.
|
105.04% | 0.006 | 16.88% | 0.41x |
|
ESPR
Esperion Therapeutics, Inc.
|
408.15% | 2.450 | 109.82% | 0.65x |
|
NKTR
Nektar Therapeutics
|
66.26% | 6.256 | 16.97% | 4.07x |
|
RIGL
Rigel Pharmaceuticals, Inc.
|
11.98% | 0.813 | 6.86% | 2.09x |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
3.72% | -1.020 | 2.42% | 2.24x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ANAB
AnaptysBio, Inc.
|
$107.6M | $66.9M | -3.74% | -97.37% | 61.8% | $98M |
|
ABBV
AbbVie, Inc.
|
$12.1B | $5.7B | 6.1% | 144.3% | 34.23% | $4.9B |
|
ESPR
Esperion Therapeutics, Inc.
|
$46M | -$10M | -60.77% | -- | -11.41% | -$23.9M |
|
NKTR
Nektar Therapeutics
|
$11.6M | -$31.5M | -54.14% | -327.67% | -267.45% | -$48.9M |
|
RIGL
Rigel Pharmaceuticals, Inc.
|
$63.8M | $23.2M | 201.85% | 299.43% | 33.19% | $22M |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$49.6M | -$40.4M | -46.15% | -47.32% | -70.53% | -$29.5M |
AnaptysBio, Inc. vs. Competitors
-
Which has Higher Returns ANAB or ABBV?
AbbVie, Inc. has a net margin of 45.83% compared to AnaptysBio, Inc.'s net margin of 10.86%. AnaptysBio, Inc.'s return on equity of -97.37% beat AbbVie, Inc.'s return on equity of 144.3%.
Company Gross Margin Earnings Per Share Invested Capital ANABAnaptysBio, Inc.99.44% $1.58 $327.9M ABBVAbbVie, Inc.72.63% $1.02 $65B -
What do Analysts Say About ANAB or ABBV?
AnaptysBio, Inc. has a consensus price target of $70.08, signalling upside risk potential of 15.75%. On the other hand AbbVie, Inc. has an analysts' consensus of $248.69 which suggests that it could grow by 5.29%. Given that AnaptysBio, Inc. has higher upside potential than AbbVie, Inc., analysts believe AnaptysBio, Inc. is more attractive than AbbVie, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ANABAnaptysBio, Inc.9 1 0 ABBVAbbVie, Inc.13 9 0 -
Is ANAB or ABBV More Risky?
AnaptysBio, Inc. has a beta of 0.318, which suggesting that the stock is 68.228% less volatile than S&P 500. In comparison AbbVie, Inc. has a beta of 0.341, suggesting its less volatile than the S&P 500 by 65.89%.
-
Which is a Better Dividend Stock ANAB or ABBV?
AnaptysBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AbbVie, Inc. offers a yield of 2.82% to investors and pays a quarterly dividend of $1.73 per share. AnaptysBio, Inc. pays -- of its earnings as a dividend. AbbVie, Inc. pays out 281.66% of its earnings as a dividend.
-
Which has Better Financial Ratios ANAB or ABBV?
AnaptysBio, Inc. quarterly revenues are $108.2M, which are smaller than AbbVie, Inc. quarterly revenues of $16.6B. AnaptysBio, Inc.'s net income of $49.6M is lower than AbbVie, Inc.'s net income of $1.8B. Notably, AnaptysBio, Inc.'s price-to-earnings ratio is -- while AbbVie, Inc.'s PE ratio is 100.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnaptysBio, Inc. is 7.73x versus 6.84x for AbbVie, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANABAnaptysBio, Inc.7.73x -- $108.2M $49.6M ABBVAbbVie, Inc.6.84x 100.02x $16.6B $1.8B
-
Which has Higher Returns ANAB or ESPR?
Esperion Therapeutics, Inc. has a net margin of 45.83% compared to AnaptysBio, Inc.'s net margin of -35.89%. AnaptysBio, Inc.'s return on equity of -97.37% beat Esperion Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ANABAnaptysBio, Inc.99.44% $1.58 $327.9M ESPREsperion Therapeutics, Inc.52.71% -$0.16 $146.5M -
What do Analysts Say About ANAB or ESPR?
AnaptysBio, Inc. has a consensus price target of $70.08, signalling upside risk potential of 15.75%. On the other hand Esperion Therapeutics, Inc. has an analysts' consensus of $6.87 which suggests that it could grow by 136.03%. Given that Esperion Therapeutics, Inc. has higher upside potential than AnaptysBio, Inc., analysts believe Esperion Therapeutics, Inc. is more attractive than AnaptysBio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ANABAnaptysBio, Inc.9 1 0 ESPREsperion Therapeutics, Inc.2 1 0 -
Is ANAB or ESPR More Risky?
AnaptysBio, Inc. has a beta of 0.318, which suggesting that the stock is 68.228% less volatile than S&P 500. In comparison Esperion Therapeutics, Inc. has a beta of 1.107, suggesting its more volatile than the S&P 500 by 10.692%.
-
Which is a Better Dividend Stock ANAB or ESPR?
AnaptysBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Esperion Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnaptysBio, Inc. pays -- of its earnings as a dividend. Esperion Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ANAB or ESPR?
AnaptysBio, Inc. quarterly revenues are $108.2M, which are larger than Esperion Therapeutics, Inc. quarterly revenues of $87.3M. AnaptysBio, Inc.'s net income of $49.6M is higher than Esperion Therapeutics, Inc.'s net income of -$31.3M. Notably, AnaptysBio, Inc.'s price-to-earnings ratio is -- while Esperion Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnaptysBio, Inc. is 7.73x versus 1.89x for Esperion Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANABAnaptysBio, Inc.7.73x -- $108.2M $49.6M ESPREsperion Therapeutics, Inc.1.89x -- $87.3M -$31.3M
-
Which has Higher Returns ANAB or NKTR?
Nektar Therapeutics has a net margin of 45.83% compared to AnaptysBio, Inc.'s net margin of -301.29%. AnaptysBio, Inc.'s return on equity of -97.37% beat Nektar Therapeutics's return on equity of -327.67%.
Company Gross Margin Earnings Per Share Invested Capital ANABAnaptysBio, Inc.99.44% $1.58 $327.9M NKTRNektar Therapeutics98.34% -$1.87 $252.2M -
What do Analysts Say About ANAB or NKTR?
AnaptysBio, Inc. has a consensus price target of $70.08, signalling upside risk potential of 15.75%. On the other hand Nektar Therapeutics has an analysts' consensus of $129.86 which suggests that it could grow by 82.62%. Given that Nektar Therapeutics has higher upside potential than AnaptysBio, Inc., analysts believe Nektar Therapeutics is more attractive than AnaptysBio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ANABAnaptysBio, Inc.9 1 0 NKTRNektar Therapeutics7 0 0 -
Is ANAB or NKTR More Risky?
AnaptysBio, Inc. has a beta of 0.318, which suggesting that the stock is 68.228% less volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.170, suggesting its more volatile than the S&P 500 by 16.958%.
-
Which is a Better Dividend Stock ANAB or NKTR?
AnaptysBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnaptysBio, Inc. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ANAB or NKTR?
AnaptysBio, Inc. quarterly revenues are $108.2M, which are larger than Nektar Therapeutics quarterly revenues of $11.8M. AnaptysBio, Inc.'s net income of $49.6M is higher than Nektar Therapeutics's net income of -$35.5M. Notably, AnaptysBio, Inc.'s price-to-earnings ratio is -- while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnaptysBio, Inc. is 7.73x versus 73.32x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANABAnaptysBio, Inc.7.73x -- $108.2M $49.6M NKTRNektar Therapeutics73.32x -- $11.8M -$35.5M
-
Which has Higher Returns ANAB or RIGL?
Rigel Pharmaceuticals, Inc. has a net margin of 45.83% compared to AnaptysBio, Inc.'s net margin of 40.17%. AnaptysBio, Inc.'s return on equity of -97.37% beat Rigel Pharmaceuticals, Inc.'s return on equity of 299.43%.
Company Gross Margin Earnings Per Share Invested Capital ANABAnaptysBio, Inc.99.44% $1.58 $327.9M RIGLRigel Pharmaceuticals, Inc.91.47% $13.54 $444.8M -
What do Analysts Say About ANAB or RIGL?
AnaptysBio, Inc. has a consensus price target of $70.08, signalling upside risk potential of 15.75%. On the other hand Rigel Pharmaceuticals, Inc. has an analysts' consensus of $51.20 which suggests that it could grow by 74.15%. Given that Rigel Pharmaceuticals, Inc. has higher upside potential than AnaptysBio, Inc., analysts believe Rigel Pharmaceuticals, Inc. is more attractive than AnaptysBio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ANABAnaptysBio, Inc.9 1 0 RIGLRigel Pharmaceuticals, Inc.3 2 0 -
Is ANAB or RIGL More Risky?
AnaptysBio, Inc. has a beta of 0.318, which suggesting that the stock is 68.228% less volatile than S&P 500. In comparison Rigel Pharmaceuticals, Inc. has a beta of 1.102, suggesting its more volatile than the S&P 500 by 10.219%.
-
Which is a Better Dividend Stock ANAB or RIGL?
AnaptysBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rigel Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnaptysBio, Inc. pays -- of its earnings as a dividend. Rigel Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ANAB or RIGL?
AnaptysBio, Inc. quarterly revenues are $108.2M, which are larger than Rigel Pharmaceuticals, Inc. quarterly revenues of $69.8M. AnaptysBio, Inc.'s net income of $49.6M is lower than Rigel Pharmaceuticals, Inc.'s net income of $268.1M. Notably, AnaptysBio, Inc.'s price-to-earnings ratio is -- while Rigel Pharmaceuticals, Inc.'s PE ratio is 1.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnaptysBio, Inc. is 7.73x versus 1.89x for Rigel Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANABAnaptysBio, Inc.7.73x -- $108.2M $49.6M RIGLRigel Pharmaceuticals, Inc.1.89x 1.57x $69.8M $268.1M
-
Which has Higher Returns ANAB or VNDA?
Vanda Pharmaceuticals, Inc. has a net margin of 45.83% compared to AnaptysBio, Inc.'s net margin of -246.76%. AnaptysBio, Inc.'s return on equity of -97.37% beat Vanda Pharmaceuticals, Inc.'s return on equity of -47.32%.
Company Gross Margin Earnings Per Share Invested Capital ANABAnaptysBio, Inc.99.44% $1.58 $327.9M VNDAVanda Pharmaceuticals, Inc.86.65% -$2.39 $339.8M -
What do Analysts Say About ANAB or VNDA?
AnaptysBio, Inc. has a consensus price target of $70.08, signalling upside risk potential of 15.75%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $14.88 which suggests that it could grow by 81.4%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than AnaptysBio, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than AnaptysBio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ANABAnaptysBio, Inc.9 1 0 VNDAVanda Pharmaceuticals, Inc.3 1 0 -
Is ANAB or VNDA More Risky?
AnaptysBio, Inc. has a beta of 0.318, which suggesting that the stock is 68.228% less volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.547, suggesting its less volatile than the S&P 500 by 45.303%.
-
Which is a Better Dividend Stock ANAB or VNDA?
AnaptysBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AnaptysBio, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ANAB or VNDA?
AnaptysBio, Inc. quarterly revenues are $108.2M, which are larger than Vanda Pharmaceuticals, Inc. quarterly revenues of $57.2M. AnaptysBio, Inc.'s net income of $49.6M is higher than Vanda Pharmaceuticals, Inc.'s net income of -$141.2M. Notably, AnaptysBio, Inc.'s price-to-earnings ratio is -- while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AnaptysBio, Inc. is 7.73x versus 2.24x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANABAnaptysBio, Inc.7.73x -- $108.2M $49.6M VNDAVanda Pharmaceuticals, Inc.2.24x -- $57.2M -$141.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
42
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
93
NBTX alert for Mar 5
Nanobiotix SA [NBTX] is up 17.92% over the past day.
Sell
45
MRNA alert for Mar 5
Moderna, Inc. [MRNA] is up 16.05% over the past day.
Buy
77
SSRM alert for Mar 5
SSR Mining, Inc. [SSRM] is up 14.97% over the past day.
